Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NBTY acquisition closes

This article was originally published in The Tan Sheet

Executive Summary

The Carlyle Group's $4 billion purchase of NBTY wraps up Oct. 1 after receiving an affirmative vote from the supplement firm's shareholders Sept. 22. Ronkonkoma, N.Y.-based NBTY is delisting from the New York Stock Exchange and shareholders are entitled to $55 in cash for each share of common stock. When the acquisition was announced in July, some analysts expected NBTY to attract higher bids during its 35-day "go-shop" period, but none materialized (1"The Tan Sheet" July 19, 2010)

You may also be interested in...



Carlyle Group's $3.8B Bid For NBTY Could Face Competition

The Carlyle Group's planned acquisition of NBTY for $3.8 billion may not be the only private equity offer to surface for the dietary supplement giant

Obesity Drug Coverage In ACA Plans May Expand With Shift In Treatment Classification Standard

Current drug classification standard was originally designed for the Medicare Part D program, which does not cover obesity drugs.

Gilead Wins Breach Of Contract Suit Against CDC But Damages, Patent Dispute Are Unresolved

Court finds government failed to promptly notify Gilead of its PrEP-related patent applications as required under agreements for supply of HIV drugs used in CDC studies. Whether Gilead will have to license government patents remains undecided.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS104566

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel